An Inflammatory Deal: Bristol Commits Up To $2.3bn To Buy IFM Therapeutics

Most of the deal's value is in milestone fees, but at $300m up front Bristol is giving IFM's Series A investors a 10X return for drug candidates that can inflame non-responsive tumors.